Oral Hypoglycemic Agents Added to Insulin Monotherapy for Type 2 Diabetes

    loading  Checking for direct PDF access through Ovid

Abstract

Clinical Question

Among patients with type 2 diabetes mellitus who do not achieve optimal glycemic control with insulin monotherapy, is the addition of oral hypoglycemic agents associated with benefits (measured by lowering of hemoglobin A1c) or adverse effects?

Bottom Line

Adding a sulfonylurea to insulin was associated with more hypoglycemic events compared with insulin alone, but this association was not observed for metformin. Adding a sulfonylurea or metformin to insulin was associated with a decrease in hemoglobin A1c of approximately 1.0%.

Related Topics

    loading  Loading Related Articles